Chasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief? (PubMed, Medicina (Kaunas)) - Sep 27, 2026 - "Suzetrigine, a highly selective inhibitor of this channel, recently gained regulatory approval for acute pain, marking a major breakthrough in non-opioid options, even though its Phase 3 efficacy was comparable to hydrocodone/acetaminophen rather than superior to it. While suzetrigine shows that NaV1.8 can be successfully targeted, it represents a regulatory and mechanistic victory rather than a complete replacement for opioids in daily practice. Progress in this field will ultimately require precise targeting, better pharmacology, and trials that better match patient phenotypes."
Journal • Review • Addiction (Opioid and Alcohol) • Pain • NAV1
|
|
Adriana-Iuliana Anghel; Athena Ribigan; Mihaela Dinu; Robert Ancuceanu
|